共 22 条
Outcomes of upper tract urothelial carcinoma with isolated lymph node involvement following surgical resection: implications for multi-modal management
被引:10
作者:
Pelcovits, Aryeh
[1
,2
,3
]
Mueller-Leonhard, Catrina
[4
]
Mega, Anthony
[1
,5
]
Amin, Ali
[1
,6
]
Kim, Simon P.
[7
]
Golijanin, Dragan
[1
,3
,8
,9
]
Gershman, Boris
[10
]
机构:
[1] Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA
[2] Rhode Isl Hosp, Dept Med, Providence, RI 02903 USA
[3] Miriam Hosp, Providence, RI 02906 USA
[4] Miriam Hosp, Lifespan Oncol Clin Res, Providence, RI 02906 USA
[5] Miriam Hosp, Dept Hematol Oncol, Providence, RI 02906 USA
[6] Miriam Hosp, Dept Pathol & Lab Med, Providence, RI 02906 USA
[7] Univ Colorado, Div Urol, Anschutz Med Ctr, Aurora, CO USA
[8] Rhode Isl Hosp, Div Urol, Providence, RI USA
[9] Miriam Hosp, Minimally Invas Urol Inst, Providence, RI 02906 USA
[10] Beth Israel Deaconess Med Ctr, Div Urol Surg, Boston, MA 02215 USA
关键词:
Urothelial cancer;
Radical nephroureterectomy;
Lymph node dissection;
Lymph node;
Survival;
Chemotherapy;
RENAL-CELL CARCINOMA;
NEOADJUVANT CHEMOTHERAPY;
BLADDER-CANCER;
RADICAL NEPHROURETERECTOMY;
ADJUVANT CHEMOTHERAPY;
ONCOLOGIC OUTCOMES;
SURVIVAL;
D O I:
10.1007/s00345-019-02897-2
中图分类号:
R5 [内科学];
R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号:
1002 ;
100201 ;
摘要:
Background There are limited data on the oncologic outcomes of upper tract urothelial carcinoma with isolated lymph node (LN) involvement (pN+ M0) following surgical resection. We examined pN+ M0 UTUC in a large, nationwide oncology dataset to characterize its natural history, describe trends in utilization of perioperative chemotherapy, and identify clinicopathologic features associated with survival. Methods We identified 794 patients aged 18-89 years who underwent radical nephroureterectomy with lymph node dissection for pN+ M0 UTUC from 2006 to 2013 in the National Cancer Database. The associations of clinicopathologic features with overall survival (OS) were evaluated using Cox regression models, and a simplified risk score was created. Results Median follow-up among survivors was 39.5 months, during which time 555 (70%) patients died. Over the study period, neoadjuvant chemotherapy utilization increased from 6.7 to 14.2% (p = 0.002), while adjuvant chemotherapy utilization remained stable (42.7 to 44.3%; p = 0.86). One-, 5-, and 8-year OS rates were 63.7%, 24.2%, and 18.7%, respectively. On multivariable analysis, older age, larger tumor size, higher pT stage, positive surgical margins, number of positive LNs, and non-receipt of adjuvant chemotherapy were independently associated with worse OS. A simplified risk score consisting of age, tumor size, pT stage, number of positive LNs, and margin status was created with predicted 5-year OS ranging from 12 to 44%. Conclusions In this large, contemporary cohort, pN+ M0 UTUC was associated with a 5-year OS of only 24%. Clinicopathologic predictors of survival after surgical resection may improve risk-stratification, counseling, and selection of patients for multimodal management.
引用
收藏
页码:1243 / 1252
页数:10
相关论文